Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

News

February 28, 2024
PRESS RELEASE: On February 22, 2024, a new research paper was published in Oncotarget, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.” continue reading »

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells

News

February 26, 2024
PRESS RELEASE: On February 8, 2024, a new research paper was published in Oncotarget, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.” continue reading »

Raw Areca Nut Betel Quid Consumption and Esophageal Cancer

Oncotarget

February 22, 2024
In this new study, researchers provide valuable insights into raw areca nut betel quid consumption and esophageal cancer. continue reading »

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel

News

February 21, 2024
PRESS RELEASE: On February 8, 2024, a new research perspective was published in Oncotarget, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.” continue reading »

NTRK Gene Fusion in Papillary Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland

News

February 19, 2024
PRESS RELEASE: On February 5, 2024, a new research paper was published in Oncotarget, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland.” continue reading »